Cargando…

An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy

BACKGROUND: Salmonella causes intracellular infections in humans. Besides quinolones, third generation cephalosporins are first line drugs used for salmonellosis therapy. An unresolved anomaly of this practice involves high relapse rates associated to quinolone- or cephalosporin-susceptible Salmonel...

Descripción completa

Detalles Bibliográficos
Autores principales: Castanheira, Sónia, López-Escarpa, David, Pucciarelli, M.Graciela, Cestero, Juan J., Baquero, Fernando, García-del Portillo, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186495/
https://www.ncbi.nlm.nih.gov/pubmed/32344200
http://dx.doi.org/10.1016/j.ebiom.2020.102771
_version_ 1783526961539186688
author Castanheira, Sónia
López-Escarpa, David
Pucciarelli, M.Graciela
Cestero, Juan J.
Baquero, Fernando
García-del Portillo, Francisco
author_facet Castanheira, Sónia
López-Escarpa, David
Pucciarelli, M.Graciela
Cestero, Juan J.
Baquero, Fernando
García-del Portillo, Francisco
author_sort Castanheira, Sónia
collection PubMed
description BACKGROUND: Salmonella causes intracellular infections in humans. Besides quinolones, third generation cephalosporins are first line drugs used for salmonellosis therapy. An unresolved anomaly of this practice involves high relapse rates associated to quinolone- or cephalosporin-susceptible Salmonella isolates in patients that are discharged clinically following initial recovery. Reduced drug accessibility to intracellular locations has been hypothesized to impair pathogen eradication although supporting evidence is lacking in vivo. Here, we uncover a novel penicillin-binding protein as the first Salmonella factor likely contributing to relapse following beta-lactam, mainly ceftriaxone, therapy. METHODS: We used Salmonella enterica serovar Typhimurium mutants lacking the alternative penicillin-binding proteins PBP2(SAL) or PBP3(SAL). Affinity of PBP2(SAL) and PBP3(SAL) for beta-lactam antibiotics was tested. Relapse after ceftriaxone therapy was analysed in the murine typhoid model. FINDINGS: S. Typhimurium does not express PBP2(SAL) or PBP3(SAL) in the Mueller-Hinton medium used for susceptibility testing. The pathogen produces these PBPs in response to acidic pH and nutrient limitation, conditions found in phagosomes of mammalian cells. PBP3(SAL) has low affinity for beta-lactams, even at acidic pH. In vitro susceptibility to ceftriaxone at low pH is strongly reduced. S. Typhimurium lacking PBP3(SAL) was unable to cause relapse in mice following ceftriaxone therapy. INTERPRETATION: The reduced capacity of ceftriaxone to clear S. Typhimurium in vivo is favoured by a switch in beta-lactam targets. This switch, involving production of the less-susceptible PBP3(SAL), remains invisible for standard procedures used in clinical therapy. We conclude that eradication of salmonellosis will be possible only upon targeting of PBP3(SAL) with novel drugs.
format Online
Article
Text
id pubmed-7186495
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71864952020-05-04 An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy Castanheira, Sónia López-Escarpa, David Pucciarelli, M.Graciela Cestero, Juan J. Baquero, Fernando García-del Portillo, Francisco EBioMedicine Research paper BACKGROUND: Salmonella causes intracellular infections in humans. Besides quinolones, third generation cephalosporins are first line drugs used for salmonellosis therapy. An unresolved anomaly of this practice involves high relapse rates associated to quinolone- or cephalosporin-susceptible Salmonella isolates in patients that are discharged clinically following initial recovery. Reduced drug accessibility to intracellular locations has been hypothesized to impair pathogen eradication although supporting evidence is lacking in vivo. Here, we uncover a novel penicillin-binding protein as the first Salmonella factor likely contributing to relapse following beta-lactam, mainly ceftriaxone, therapy. METHODS: We used Salmonella enterica serovar Typhimurium mutants lacking the alternative penicillin-binding proteins PBP2(SAL) or PBP3(SAL). Affinity of PBP2(SAL) and PBP3(SAL) for beta-lactam antibiotics was tested. Relapse after ceftriaxone therapy was analysed in the murine typhoid model. FINDINGS: S. Typhimurium does not express PBP2(SAL) or PBP3(SAL) in the Mueller-Hinton medium used for susceptibility testing. The pathogen produces these PBPs in response to acidic pH and nutrient limitation, conditions found in phagosomes of mammalian cells. PBP3(SAL) has low affinity for beta-lactams, even at acidic pH. In vitro susceptibility to ceftriaxone at low pH is strongly reduced. S. Typhimurium lacking PBP3(SAL) was unable to cause relapse in mice following ceftriaxone therapy. INTERPRETATION: The reduced capacity of ceftriaxone to clear S. Typhimurium in vivo is favoured by a switch in beta-lactam targets. This switch, involving production of the less-susceptible PBP3(SAL), remains invisible for standard procedures used in clinical therapy. We conclude that eradication of salmonellosis will be possible only upon targeting of PBP3(SAL) with novel drugs. Elsevier 2020-04-25 /pmc/articles/PMC7186495/ /pubmed/32344200 http://dx.doi.org/10.1016/j.ebiom.2020.102771 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research paper
Castanheira, Sónia
López-Escarpa, David
Pucciarelli, M.Graciela
Cestero, Juan J.
Baquero, Fernando
García-del Portillo, Francisco
An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy
title An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy
title_full An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy
title_fullStr An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy
title_full_unstemmed An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy
title_short An alternative penicillin-binding protein involved in Salmonella relapses following ceftriaxone therapy
title_sort alternative penicillin-binding protein involved in salmonella relapses following ceftriaxone therapy
topic Research paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186495/
https://www.ncbi.nlm.nih.gov/pubmed/32344200
http://dx.doi.org/10.1016/j.ebiom.2020.102771
work_keys_str_mv AT castanheirasonia analternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT lopezescarpadavid analternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT pucciarellimgraciela analternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT cesterojuanj analternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT baquerofernando analternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT garciadelportillofrancisco analternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT castanheirasonia alternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT lopezescarpadavid alternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT pucciarellimgraciela alternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT cesterojuanj alternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT baquerofernando alternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy
AT garciadelportillofrancisco alternativepenicillinbindingproteininvolvedinsalmonellarelapsesfollowingceftriaxonetherapy